Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / BPIFA1

BPIFA1

Basics

Aliases:
This biomarker is also known as:
  • Nasopharyngeal Carcinoma-Related Protein,
  • Palate, Lung And Nasal Epithelium Associated,
  • NASG,
  • Ligand-Binding Protein RYA3,
  • BA49G10.5,
  • Tracheal Epithelium-Enriched Protein,
  • Lung-Specific Protein X,
  • SPURT,
  • Secretory Protein In Upper Respiratory Tracts,
  • BPI Fold-Containing Family A Member 1,
  • PLUNC,
  • Protein Plunc,
  • SPLUNC1,
  • Palate, Lung And Nasal Epithelium Carcinoma Associated,
  • BPI Fold Containing Family A, Member 1,
  • LUNX,
  • Tracheal Epithelium Enriched Protein,
  • Von Ebner Protein Hl,
  • Palate Lung And Nasal Epithelium Clone Protein,

View in BioMuta

Description…

The BPIFA1 gene was formerly known as PLUNC. This human gene is the homolog of murine Plunc, and shows the same expression pattern as murine Plunc. Both are expressed in the upper airways and nasopharyngeal regions. Human BPIFA1 may be involved in the airway inflammatory response after exposure to irritants and may be associated with tumor progression. BPIFA1 may also play a role in innate immune responses of the upper airways. And it may serve as a potential molecular marker for detection of micrometastasis in non-small-cell lung cancer. Multiple transcript variants resulting from alternative splicing in the 3' UTR have been detected, but only three full length variants have been isolated.

Attributes

QA State: Under Review
Type: Gene
Short Name:
HGNC Name: BPIFA1

Datasets

There are no datasets associated with this biomarker.

Organs

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Publications

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Resources

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.